BACKGROUND: Secretory phospholipase A2 (sPLA2) enzymes are considered to play a role in atherosclerosis. sPLA2 activity encompasses several sPLA2 isoenzymes, including sPLA2-V. Although observational studies show a strong association between elevated sPLA2 activity and CHD, no assay to measure sPLA2-V levels exists, and the only evidence linking the sPLA2-V isoform to atherosclerosis progression comes from animal studies. In the absence of an assay that directly quantifies sPLA2-V levels, we used PLA2G5 mRNA levels in a novel, modified Mendelian randomization approach to investigate the hypothesized causal role of sPLA2-V in coronary heart disease (CHD) pathogenesis. METHODS AND RESULTS: Using data from the Advanced Study of Aortic Pathology, we identified the single-nucleotide polymorphism in PLA2G5 showing the strongest association with PLA2G5 mRNA expression levels as a proxy for sPLA2-V levels. We tested the association of this SNP with sPLA2 activity and CHD events in 4 prospective and 14 case-control studies with 27 230 events and 70 500 controls. rs525380C>A showed the strongest association with PLA2G5 mRNA expression (P=5.1×10(-6)). There was no association of rs525380C>A with plasma sPLA2 activity (difference in geometric mean of sPLA2 activity per rs525380 A-allele 0.4% (95% confidence intervals [-0.9%, 1.6%]; P=0.56). In meta-analyses, the odds ratio for CHD per A-allele was 1.02 (95% confidence intervals [0.99, 1.04]; P=0.20). CONCLUSIONS: This novel approach for single-nucleotide polymorphism selection for this modified Mendelian randomization analysis showed no association between rs525380 (the lead single-nucleotide polymorphism for PLA2G5 expression, a surrogate for sPLA2-V levels) and CHD events. The evidence does not support a causal role for sPLA2-V in CHD.
BACKGROUND: Secretory phospholipase A2 (sPLA2) enzymes are considered to play a role in atherosclerosis. sPLA2 activity encompasses several sPLA2 isoenzymes, including sPLA2-V. Although observational studies show a strong association between elevated sPLA2 activity and CHD, no assay to measure sPLA2-V levels exists, and the only evidence linking the sPLA2-V isoform to atherosclerosis progression comes from animal studies. In the absence of an assay that directly quantifies sPLA2-V levels, we used PLA2G5 mRNA levels in a novel, modified Mendelian randomization approach to investigate the hypothesized causal role of sPLA2-V in coronary heart disease (CHD) pathogenesis. METHODS AND RESULTS: Using data from the Advanced Study of Aortic Pathology, we identified the single-nucleotide polymorphism in PLA2G5 showing the strongest association with PLA2G5 mRNA expression levels as a proxy for sPLA2-V levels. We tested the association of this SNP with sPLA2 activity and CHD events in 4 prospective and 14 case-control studies with 27 230 events and 70 500 controls. rs525380C>A showed the strongest association with PLA2G5 mRNA expression (P=5.1×10(-6)). There was no association of rs525380C>A with plasma sPLA2 activity (difference in geometric mean of sPLA2 activity per rs525380 A-allele 0.4% (95% confidence intervals [-0.9%, 1.6%]; P=0.56). In meta-analyses, the odds ratio for CHD per A-allele was 1.02 (95% confidence intervals [0.99, 1.04]; P=0.20). CONCLUSIONS: This novel approach for single-nucleotide polymorphism selection for this modified Mendelian randomization analysis showed no association between rs525380 (the lead single-nucleotide polymorphism for PLA2G5 expression, a surrogate for sPLA2-V levels) and CHD events. The evidence does not support a causal role for sPLA2-V in CHD.
Authors: Stephen B Montgomery; Micha Sammeth; Maria Gutierrez-Arcelus; Radoslaw P Lach; Catherine Ingle; James Nisbett; Roderic Guigo; Emmanouil T Dermitzakis Journal: Nature Date: 2010-03-10 Impact factor: 49.962
Authors: Tanja Zeller; Philipp Wild; Silke Szymczak; Maxime Rotival; Arne Schillert; Raphaele Castagne; Seraya Maouche; Marine Germain; Karl Lackner; Heidi Rossmann; Medea Eleftheriadis; Christoph R Sinning; Renate B Schnabel; Edith Lubos; Detlev Mennerich; Werner Rust; Claire Perret; Carole Proust; Viviane Nicaud; Joseph Loscalzo; Norbert Hübner; David Tregouet; Thomas Münzel; Andreas Ziegler; Laurence Tiret; Stefan Blankenberg; François Cambien Journal: PLoS One Date: 2010-05-18 Impact factor: 3.240
Authors: Y Asaoka; K Yoshida; Y Sasaki; Y Nishizuka; M Murakami; I Kudo; K Inoue Journal: Proc Natl Acad Sci U S A Date: 1993-01-15 Impact factor: 11.205
Authors: Gilberto Vargas-Alarcón; Carlos Posadas-Romero; Teresa Villarreal-Molina; Edith Alvarez-León; Javier Angeles-Martinez; María Elena Soto; Irma Monroy-Muñoz; Juan Gabriel Juárez; Carlos Jerges Sánchez-Ramírez; Julian Ramirez-Bello; Silvestre Ramírez-Fuentes; José Manuel Fragoso; José Manuel Rodríguez-Pérez Journal: Biomed Res Int Date: 2014-05-18 Impact factor: 3.411
Authors: Ani Manichaikul; Xin-Qun Wang; Li Li; Jeanette Erdmann; Guillaume Lettre; Joshua C Bis; Dawn Waterworth; Mary Cushman; Nancy S Jenny; Wendy S Post; Walter Palmas; Michael Y Tsai; Lars Wallentin; Harvey White; Heribert Schunkert; Christopher J O'Donnell; David M Herrington; Stephen S Rich; Michelle L O'Donoghue; Annabelle Rodriguez Journal: PLoS One Date: 2018-10-05 Impact factor: 3.752
Authors: Daniel I Swerdlow; Karoline B Kuchenbaecker; Sonia Shah; Reecha Sofat; Michael V Holmes; Jon White; Jennifer S Mindell; Mika Kivimaki; Eric J Brunner; John C Whittaker; Juan P Casas; Aroon D Hingorani Journal: Int J Epidemiol Date: 2016-06-24 Impact factor: 7.196